Evidence map›Paper›PMID 37560552›Full record

ArticleJournal of medical cases2023

Myocarditis Related to the Use of Mesalazine.

Michaela Kyriakou, Stefanos Sakellaropoulos, Thrasos Constantinides, Grigorios Chatzantonis, Panayiotis Avraamides, Andreas Mitsis

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michaela KyriakouCardiology Department, Nicosia General Hospital, Nicosia, Cyprus.
Stefanos SakellaropoulosDepartment of Internal Medicine, Cardiology Clinic, Kantonsspital Baden, Baden, Switzerland.
Thrasos ConstantinidesNicosia Heart Center, Nicosia, Cyprus.
Grigorios ChatzantonisDepartment of Cardiology I, University Hospital Munster, Munster, Germany.
Panayiotis AvraamidesCardiology Department, Nicosia General Hospital, Nicosia, Cyprus.
Andreas MitsisCardiology Department, Nicosia General Hospital, Nicosia, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocarditis is a rare complication of therapy with mesalazine, a drug traditionally used in the treatment of inflammatory bowel disease. We report a case of a 32-year-old man with a recent diagnosis of ulcerative colitis, who presented to our hospital with chest pain and elevated troponin, 12 days following initiation of mesalazine. Diagnosis of myocarditis was confirmed with cardiac magnetic resonance imaging (CMR), which showed subepicardial gadolinium enhancement in the basal lateral/inferolateral segment of the heart. The patient's clinical condition improved upon stopping mesalazine and the follow-up CMR demonstrated resolution of the previous findings. Mesalazine can cause myocarditis early after initiation and clinicians should be aware of this rare yet serious cardiotoxic effect, as the discontinuation of the medication is the mainstay of treatment and leads to significant recovery.

Indexed as

Cardiac magnetic resonanceInflammatory bowel diseaseMesalazineMyocarditisUlcerative colitis

Identifiers

PMID37560552
PMCPMC10409542

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.